<SEC-DOCUMENT>0001493152-25-004354.txt : 20250131
<SEC-HEADER>0001493152-25-004354.hdr.sgml : 20250131
<ACCEPTANCE-DATETIME>20250131100446
ACCESSION NUMBER:		0001493152-25-004354
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250131
DATE AS OF CHANGE:		20250131

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REED'S, INC.
		CENTRAL INDEX KEY:			0001140215
		STANDARD INDUSTRIAL CLASSIFICATION:	BOTTLED & CANNED SOFT DRINKS CARBONATED WATERS [2086]
		ORGANIZATION NAME:           	04 Manufacturing
		IRS NUMBER:				352177773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-84925
		FILM NUMBER:		25576390

	BUSINESS ADDRESS:	
		STREET 1:		501 MERRITT 7
		CITY:			NORWALK
		STATE:			CT
		ZIP:			06851
		BUSINESS PHONE:		800 997 3337

	MAIL ADDRESS:	
		STREET 1:		501 MERRITT 7
		CITY:			NORWALK
		STATE:			CT
		ZIP:			06851

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REED'S INC
		DATE OF NAME CHANGE:	20140512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REEDS INC
		DATE OF NAME CHANGE:	20020122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORIGINAL BEVERAGE CORP /
		DATE OF NAME CHANGE:	20010508

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DENG Shufen
		CENTRAL INDEX KEY:			0001980084
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		ROOMS 3006-07, CHINA RESOURCES BUILDING
		STREET 2:		26 HARBOUR ROAD, WANCHAI
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			000000
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001104659-23-067830</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: DENG Shufen -->
          <cik>0001980084</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>4</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <dateOfEvent>12/30/2024</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001140215</issuerCIK>
        <issuerCUSIP>758338305</issuerCUSIP>
        <issuerName>Reed's, Inc.</issuerName>
        <address>
          <com:street1>501 Merritt 7 Corporate Park</com:street1>
          <com:city>Norwalk</com:city>
          <com:stateOrCountry>CT</com:stateOrCountry>
          <com:zipCode>06851</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Ruba Qashu</personName>
          <personPhoneNum>(949) 355-5405</personPhoneNum>
          <personAddress>
            <com:street1>Barton LLP</com:street1>
            <com:street2>711 Third Avenue 14th Floor</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10017</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001979652</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>D&amp;D Source of Life Holding Ltd.</reportingPersonName>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>E9</citizenshipOrOrganization>
        <soleVotingPower>27139519.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>27139519.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>27139519.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>59.5</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001980084</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Shufen Deng</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>K3</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>0.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock</securityTitle>
        <issuerName>Reed's, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>501 Merritt 7 Corporate Park</com:street1>
          <com:city>Norwalk</com:city>
          <com:stateOrCountry>CT</com:stateOrCountry>
          <com:zipCode>06851</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item5>
        <percentageOfClassSecurities>D&amp;D Source of Life Holding Ltd. ("D&amp;D") has sole voting and dispositive power over 27,139,519 shares of Issuer's common stock, $0.0001 par value, ("Shares") representing 59.5% of the outstanding Shares of common stock of the Issuer. Shufen Deng no longer may be deemed to be a beneficial owner of Shares of the Issuer. Era Regenerative Medicine Limited, a BVI company, owns all outstanding shares in D&amp;D. The calculation is based on a denominator of 45,603,355 which includes (i) 30,665,365 Shares outstanding as of November 21, 2024 as disclosed in the Issuer's Definitive Information Statement on Schedule 14C filed on December 31, 2024, (ii) 232,108 Shares issuable upon exercise of currently exercisable warrants and (iii) 14,705,882 Shares issued by the Issuer in a private placement on December 30, 2024 as reported on Current Report on Form 8-K, as filed January 6, 2025.</percentageOfClassSecurities>
        <numberOfShares>D&amp;D has sole voting and dispositive power over 27,139,519 Shares representing 59.5% of the outstanding Shares of the Issuer. Shufen Deng no longer may be deemed to be a beneficial owner of Shares of the Issuer. Shufen Deng previously disclaimed beneficial ownership of the Shares except for her pecuniary interest therein as sole stockholder and director of D&amp;D.</numberOfShares>
        <transactionDesc>On December 31, 2024, Shufen Deng resigned from her position as director of D&amp;D and assigned and transferred all issued and outstanding shares of common stock of D&amp;D to an unaffiliated third party, Era Regenerative Medicine Limited, a BVI company.</transactionDesc>
      </item5>
      <item6>
        <contractDescription>Item 6 is supplemented by adding the following to the end of the disclosures therein set forth: On December 31, 2024, Shufen Deng resigned from her position as director of D&amp;D and assigned and transferred all issued and outstanding shares of common stock of D&amp;D to an unaffiliated third party, Era Regenerative Medicine Limited, a BVI company. On January 24, 2025, D&amp;D and the Issuer entered into an Amendment to the Shareholders Agreement dated May 25, 2023 (the "Amendment to Shareholders Agreement"), updating the agreement to incorporating previously agreed terms: so long as D&amp;D owns 25% or more of the Issuer's issued and outstanding common stock, (1) D&amp;D shall have the right to designate three individuals for appointment to the board of the Issuer, two of which shall be "independent directors" as defined in the rules of the Nasdaq Stock Market, (2) D&amp;D shall have the right to designate one board observer and (3) the size of the board will not exceed nine members without consent of both D&amp;D's independent designated directors. On January 24, 2025, D&amp;D entered into a Board Observer Agreement with the Issuer governing D&amp;D's right to designate a board observer. Such board observer right permits the observer's attendance at board meetings and participation in discussions at such meetings. The agreement further provides for indemnification and advancement of expenses from the Issuer to the same extent provided by the Issuer to its directors and for reimbursement of reasonable out-of-pocket expenses incurred by the observer in connection with attending meeting, subject to the Issuer's policies in effect. Any individual's service as the observer is conditioned on such individual's execution of an agreement with the Issuer that preserves the confidentiality of Issuer information and board discussions. D&amp;D designated Mr. Yumin Dai to be the board observer.
On January 24, 2025, D&amp;D and Shufen Deng executed the Joint Filing Termination.
The foregoing descriptions of the Amendment to Shareholders Agreement, the Board Observer Agreement and the Joint Filing Termination do not purport to be complete and are qualified in their entirety by reference to the complete text of such documents, which are attached to this Schedule 13D/A and are incorporated herein by reference.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Amendment to Shareholders Agreement between the Issuer and D&amp;D dated January 24, 2025 (Incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K as filed January 28, 2025)
Board Observer Agreement between the Issuer and D&amp;D dated January 24, 2025 (Incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K as filed January 28, 2025)
Joint Filing Termination dated January 24, 2025, attached hereto as Exhibit A</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>D&amp;D Source of Life Holding Ltd.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ D&amp;D Source of Life Holding Ltd</signature>
          <title>Qi Meng, on behalf of Era Regenerative Medicine Limited, a BVI company, its sole shareholder</title>
          <date>01/24/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Shufen Deng</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Shufen Deng</signature>
          <title>individual</title>
          <date>01/24/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>exa.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
13D/A<BR>
JOINT FILING AGREEMENT TERMINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the undersigned is a party to that certain Joint Filing Agreement, dated as of June 5, 2023 (the &ldquo;Joint Filing Agreement&rdquo;).
In accordance with the Joint Filing Agreement, each of the undersigned hereby agrees that the Joint Filing Agreement is terminated, effective
as of December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Joint Filing Agreement Termination on January 24, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D&amp;D
SOURCE OF LIFE HOLDING LTD.</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Era Regenerative Medicine Limited, a BVI company</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its: </FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sole Shareholder</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed:&nbsp; </FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Qi Meng</I></FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qi Meng</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its: </FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHUFEN
    DENG</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Shufen Deng</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
